Fig. 3: In vitro therapeutic potential of Pg-Fe-hMSC in mouse LECs.

a ATP levels, b Intracellular ROS levels, c Mitochondrial membrane potential (MMP) levels, and d Cell viability of bleomycin-treated TC-1 cells (BLM-TC-1) after treatment with different engineered hMSCs (n = 3, biologically independent cells for each). Impacts of Pg treatment on e ATP levels, f Intracellular ROS levels, g MMP levels, and h Cell viability of BLM-TC-1 cells (n = 3, biologically independent cells for each). Impacts of PGC-1α expression on i ATP levels, j Intracellular ROS levels, k MMP levels, and l Cell viability of BLM-TC-1 cells (n = 3, biologically independent cells for each). m Illustration showing the possible therapeutic mechanism of treating hMSC with Pg for augmented mitochondrial transfer via promoting the PGC-1α-dependent mitochondrial biogenesis. Data are presented as means ± SD. Statistical significance was analyzed using ordinary one-way ANOVA.